Japan Tobacco Inc. : - Listing on the Japanese National Health Insurance Drug Price List and Launch of CORECTIM Ointment 0.5% for the Treatment of Atopic Dermatitis in Japan

Japan Tobacco Inc. (JT) (TSE: 2914) and Torii Pharmaceutical Co., Ltd. (Torii) (TSE: 4551) announced today that drug price of CORECTIM Ointment 0.5% (generic name: delgocitinib), a Janus kinase (JAK) inhibitor, was placed on the Japanese National Health Insurance (NHI) drug price list as of today.

On January 23, 2020, JT received manufacturing and marketing approval for this drug for an indication of atopic dermatitis in Japan. Torii plans to launch the drug in Japan on June 24, 2020.

CORECTIM Ointment 0.5% is a non-steroidal topical product and the world's first topical JAK inhibitor that improves atopic dermatitis by inhibiting the action of JAKs, which play a key role in immune activation signaling in cells, by suppressing the overactivation of immune responses. In the Phase 3 comparative clinical study in patients with atopic dermatitis (aged 16) for CORECTIM Ointment 0.5% conducted in Japan, the primary endpoint of efficacy, the percentage change of the mEASI score from baseline, has met superiority to the placebo, and safety of long-term administration was also confirmed.

JT and Torii expect CORECTIM Ointment 0.5% to be a new option of treatment for patients with atopic dermatitis in Japan. In addition, the Phase 3 clinical study in pediatric patients with atopic dermatitis (aged 2 to

ABOUT Atopic Dermatitis

Atopic dermatitis is a chronic and pruritic inflammatory skin disease. It is thought to develop through exposure to various irritants or allergens for patients with a physiological abnormality of the skin (dry skin and abnormal skin barrier function).

Japan Tobacco Inc. is a leading international tobacco company with operations in more than 130 countries. With approximately 62,000 employees, it manufactures and sells some of the world's best-known brands including Winston, Camel, MEVIUS and LD. The JT Group is committed to investing in Reduced-Risk Products (RRP) and currently markets its tobacco vapor products under its Ploom brand and various ecigarette products under its Logic brand. The Group is also present in the pharmaceutical and processed food businesses.

Contact:

Dinesh Babu Thotakura

Tel: [phone]

Email: [e-mail]

(C) 2020 Electronic News Publishing, source ENP Newswire